Published in Clin Trials on August 01, 2011
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol (2013) 1.08
In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. AIDS Res Hum Retroviruses (2013) 0.87
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. J Acquir Immune Defic Syndr (2013) 0.85
Adjusting for unknown bias in non-inferiority clinical trials. Stat Biopharm Res (2013) 0.85
A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect. Stat Biopharm Res (2015) 0.84
Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer. BMJ Open (2014) 0.75
Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients. J Oncol Pract (2016) 0.75
Choice of non-inferiority (NI) margins does not protect against degradation of treatment effects on an average--an observational study of registered and published NI trials. PLoS One (2014) 0.75
Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials. Stat Methods Med Res (2016) 0.75
On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy. J Biopharm Stat (2015) 0.75
Defining the noninferiority margin and analysing noninferiority: An overview. Br J Clin Pharmacol (2017) 0.75
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med (2000) 5.06
Current issues in non-inferiority trials. Stat Med (2008) 4.72
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med (1995) 4.71
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med (1997) 3.49
Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med (2003) 2.53
Addressing missing data in clinical trials. Ann Intern Med (2011) 2.43
Design and analysis of non-inferiority mortality trials in oncology. Stat Med (2003) 2.24
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2004) 1.84
Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol (2005) 1.75
Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med (2006) 1.47
Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis (2008) 1.32
Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions. Stat Med (2008) 1.23
Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Stat Med (2008) 1.18
Evaluation of active control trials in AIDS. J Acquir Immune Defic Syndr (1990) 1.17
Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol (2007) 1.04
Clinical trials: discerning hype from substance. Ann Intern Med (2010) 1.02
Treatment evaluation in active control studies. Cancer Treat Rep (1987) 0.81
Issues in using progression-free survival when evaluating oncology products. J Clin Oncol (2009) 1.78
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog (2012) 1.70
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist (2013) 1.52
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res (2012) 1.31
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res (2013) 1.27
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res (2008) 1.17
HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog (2012) 1.14
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist (2011) 1.00
Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection. Clin Infect Dis (2013) 0.93
Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS One (2013) 0.91
Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection. J Acquir Immune Defic Syndr (2013) 0.91
Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate. J Acquir Immune Defic Syndr (2016) 0.85
A 15-year study of the impact of community antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers. AIDS (2015) 0.83
Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection. J Virol (2014) 0.78
Association between alcohol use and sexually transmitted infection incidence among kenyan women engaged in transactional sex. AIDS Behav (2014) 0.75
On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy. J Biopharm Stat (2015) 0.75
Prevalence and correlates of genital warts in Kenyan female sex workers. Sex Transm Dis (2012) 0.75